- Business Wire•yesterdayRosettaGX Reveal™ Analytical Validation Study Featured on the Cover of the October Issue of Cancer Cytopathology
Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostics, announces that an article highlighting the analytical validation data from a study of the Company’s novel, microRNA-based assay for the classification of indeterminate thyroid nodules is featured on the cover of the October issue of the peer-reviewed journal, Cancer Cytopathology.
- Business Wire•5 days ago
Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostics, announces the appointment of Mark R. Willig as Chief Commercial Officer.
- Business Wire•22 days agoRosetta Genomics Fortifies Intellectual Property Portfolio with Two New Patent Allowances for its Novel microRNA Platform Technology
Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company has added two new patent allowances to its intellectual property portfolio for its microRNA platform technology.
Rosetta Genomics, Ltd. (ROSG)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||0.61 x 1000|
|Ask||0.62 x 900|
|Day's Range||0.60 - 0.64|
|52wk Range||0.55 - 2.42|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-0.64|
|Avg Vol (3m)||141,370|
|Dividend & Yield||N/A (N/A)|